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KCNQ channel openers reverse depressive
symptoms via an active resilience mechanism
Allyson K. Friedman1,2, Barbara Juarez1,3, Stacy M. Ku1,3, Hongxing Zhang1, Rhodora C. Calizo1,
Jessica J. Walsh1,3, Dipesh Chaudhury1, Song Zhang1, Angel Hawkins1, David M. Dietz4, James W. Murrough4,5,6,
Maria Ribadeneira7, Erik H. Wong7, Rachael L. Neve8 & Ming-Hu Han1,4,6
Less than half of patients suffering from major depressive disorder, a leading cause of
disability worldwide, achieve remission with current antidepressants, making it imperative to
develop more effective treatment. A new therapeutic direction is emerging from the increased
understanding of natural resilience as an active stress-coping process. It is known that
potassium (Kþ ) channels in the ventral tegmental area (VTA) are an active mediator of
resilience. However, no druggable targets have been identiﬁed to potentiate active resilience
mechanisms. In the chronic social defeat stress model of depression, we report that
KCNQ-type Kþ channel openers, including FDA-approved drug retigabine (ezogabine), show
antidepressant efﬁcacy. We demonstrate that overexpression of KCNQ channels in the VTA
dopaminergic neurons and either local infusion or systemic administration of retigabine
normalized neuronal hyperactivity and depressive behaviours. These ﬁndings identify KCNQ
as a target for conceptually novel antidepressants that function through the potentiation of
active resilience mechanisms.
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e previously demonstrated that chronic social
defeat stress provides an excellent model of both
stress-induced depression and resilience1–6.
Interestingly, resilient mice regulate more genes in the ventral
tegmental area (VTA) than the susceptible (depressed)
subpopulation. This supports the new concept that resilience
is not a passive absence of stress-induced depression, but
actually is an active stress-coping process by which resilient
mice homeostatically maintain their healthy behaviours1,3.
Consistently, at the functional level, resilient mice use more ion
channels, including actively regulating several Kþ channels, to
stabilize VTA dopaminergic (DA) neurons and counteract the
pathologic hyperactivity of these neurons seen in the susceptible
subgroup3,7,8, further supporting the active resilience concept9–11.
Importantly, recent studies have demonstrated that promoting
resilience mechanisms achieves treatment efﬁcacy3,7. These
studies open an avenue to a conceptually innovative treatment
for depression. However, no druggable targets have been
identiﬁed so far to potentiate the active resilience mechanisms.
With the goal of therapeutically potentiating this active ionic
mechanism, we aimed to identify a behaviourally essential
component of the upregulated Kþ currents in resilient mice to
utilize as a possible drug target. In our previous microarray
analysis1, among the upregulated channels in the VTA of resilient
mice that have therapeutic potential as a drug target, we found
KCNQ3 (Kv7.3), a slow voltage-activated Kþ channel12,13.
Consistent with the microarray study indicating KCNQ3
upregulation, we previously functionally demonstrated a
remarkable increase in this sustained current in the resilient
phenotype3. Further, in vivo intra-VTA blockade of KCNQ
channels by XE-991, a KCNQ blocker, in the mice previously
classiﬁed as resilient exhibited social avoidance behaviours
similar to susceptible animals14,15. Together, these data
indicate that KCNQ may be involved in maintaining the stable
resilient phenotype and that the normal ﬁring status of
VTA DA neurons is dependent on XE-991 sensitive currents.
In addition, it is known that these XE-991-sensitive currents
include KCNQ2/3 heterodimers that exhibit an 11-fold larger
current compared with KCNQ2 or KCNQ3 homomers12,16.
Therefore, the increased KCNQ3 seen in resilient mice1 may play
a functional role in stabilizing VTA neuronal activity at the
cellular level17,18.
Results
KCNQ3 overexpression normalizes depressive phenotype. To
selectively investigate the KCNQ as a potential therapeutic target
through promoting resilience, we used a viral-mediated gene
therapy strategy to directly test the hypothesis that an increase in
KCNQ-mediated current would relieve depressive symptoms in
the susceptible (depressed) mice. To this end, we overexpressed
KCNQ3, which is known to form heteromers with KCNQ2 and
produce a stabilizing effect on neuronal activity as stated above,
selectively in the VTA DA neurons of susceptible mice and tested
whether it can induce an antidepressant effect. To restrict the
expression of KCNQ3 channels in VTA DA neurons, we used
TH-Cre mice and Cre-inducible loxP-STOP-loxP herpes simplex
virus (HSV-LS1L-KCNQ3-eYFP), while using HSV-LS1L-eYFP
as control. The viral vectors were stereotaxically injected bilat-
erally into the VTA of TH-Cre susceptible mice (Fig. 1a,b), and
morphological validation showed cell type-speciﬁc expression
(Fig. 1c,d). Our further in vivo experiments showed that the
previously susceptible mice expressing KCNQ3 spend more time
interacting with a social target in the interaction zone (Fig. 1e),
and consistently, less time in the corner zone (Fig. 1f), without
altering overall locomotor activity (Fig. 1g). Sucrose preference
was increased signiﬁcantly following KCNQ3 expression in the
susceptible mice, further supporting the antidepressant effect of
KCNQ3 channel overexpression (Fig. 1h). Following behavioural
testing, in vitro slice recordings revealed that KCNQ3-expressing
neurons had signiﬁcantly lower VTA DA neuron ﬁring activity
(Fig. 1i) as compared with the eYFP control group.
Given the functional heterogeneity of VTA projections 2,19,20,
we next performed viral upregulation of KCNQ3 in the VTA
neurons that project either to the nucleus accumbens (NAc) or to
the medial prefrontal cortex (mPFC). To achieve this, we
utilized a duel viral approach to upregulate KCNQ3 in a
projection-speciﬁc manner. We injected a retrograding
AAV2/5-Cre into either mPFC or the NAc and expressed a
Cre-dependent HSV-LS1L-KCNQ3-eYFP in the VTA of
susceptible mice (Fig. 1j). This allows for the selective
expression in the VTA-NAc or VTA-mPFC pathway
(Supplementary Fig. 1). Following expression of KCNQ3, in the
VTA-NAc pathway, but not the VTA-mPFC pathway, of
susceptible mice resulted in a reversal of depressive behaviours,
with previously socially avoidant mice interacting with the social
target and spending less time in the corner (Fig. 1k,l), without
altering overall locomotor activity (Fig. 1m). Sucrose preference
was increased signiﬁcantly following KCNQ3 expression in the
VTA-NAc but no VTA-mPFC neurons of susceptible mice
(Fig. 1n). Furthermore, KCNQ3 expression selectively in GABA
neurons of the VTA had no antidepressant action in susceptible
mice (Supplementary Fig. 2). These observations highlight the
diverse responses of VTA DA neuron populations to stress, and
suggests that VTA-NAc DA neurons may play a key role in
mediating resilience phenotype. The reversal of behavioural and
cellular abnormalities in the key circuit of susceptible mice
conﬁrms the functional contribution of KCNQ to resilience, and
indicates that KCNQ is a valid target for an antidepressant
treatment.
Intra-VTA infusion of KCNQ openers. As a potential ther-
apeutic strategy for depression, we investigated currently available
pharmacological agents that potentiate KCNQ channels. First, we
validated in VTA brain slice preparation the function of three
KCNQ channel openers21–23, including ﬂupirtine, retigabine and
BMS-204352. All three agents when bath applied to in vitro slice
preparation dose-dependently decreased the hyperactivity
observed in the VTA DA neurons of susceptible mice
(Supplementary Fig. 3). To directly test if these KCNQ openers
could reverse depressive behaviours, susceptible mice received
cannulas into the VTA and were behaviourally tested following a
single intra-VTA microinfusion of ﬂupirtine (0.3 mg), retigabine
(0.1 mg) or BMS-204352 (0.1 mg) (Fig. 2a,b). We found that
increasing KCNQ channel function using these pharmacological
agents increased time spent with the social
target in the interaction zone, reversing the social avoidant
behaviour in the previously susceptible mice (Fig. 2c). This was
complemented by a corresponding decrease in the amount of
time spent in the corner zone (Fig. 2d) with no overall change in
locomotor activity (Fig. 2e). A reversal of depression-related
behaviours was also observed post infusion as assessed by an
increase in sucrose preference (Fig. 2f). Finally, during the forced
swim test (FST), a widely used animal test predictive of
antidepressant action, the time spent immobile decreased in
susceptible mice that were infused with pharmacological KCNQ
openers (Fig. 2g). Together, these consistent antidepressant effects
strongly support that upregulation of KCNQ channel functions in
the VTA is a valid approach to potentiate the active resilience
mechanism, and that KCNQ channels are a potential druggable
target for depression treatment.
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Figure 1 | VTA DA neuron- and VTA-NAc-speciﬁc overexpression of KCNQ3 channels normalizes depression-like behaviours and neuronal
hyperactivity. (a,b) In vivo experimental design. (c) Confocal image showing co-expression of HSV-LS1L-KCNQ3-eYFP expression (green) in VTA DA
neurons (red) of TH-Cre susceptible mice (scale bar, 50mm). (d) Quantiﬁcation shows that 98±0.6% of KNCQ3-eYFP-expressing cells are THþ
(2–3 sections per mouse from three mice). (e) HSV-LS1L-KCNQ3-eYFP viral expression in VTA DA neurons in susceptible mice increases social interaction
time with target (t18¼ 3.88, **Po0.01, n¼ 10) and (f) decreases corner zone time (t18¼ 2.63, *Po 0.05, n¼ 10) compared with HSV-LS1L-eYFP control
virus. (g) There is no effect on locomotor activity (t18¼0.80, P¼0.43, n¼ 10). (h) Sucrose preference 12 h following social interaction (t18¼ 3.74,
*Po0.05, n¼ 10). (i) Sample traces and statistic ﬁring data obtained from virally infected VTA DA neurons show a decrease in the HSV-LS1L-KCNQ3-eYFP
group compared with the HSV-LS1L-eYFP control virus group (t49¼ 5.54, ***Po0.001, n¼ 22–29 cells, 6–8 mice per group). (j) Experimental timeline of
projection-speciﬁc overexpression of KCNQ3 in the VTA and schematic of viral injection of retrograding AAV2/5-Cre into the NAc or mPFC and injection
Cre-dependent HSV-LS1L-KCNQ3-eYFP into the VTA of susceptible mice. (k) HSV-LS1L-KCNQ3-eYFP viral expression in NAc projecting VTA neurons in
susceptible mice increases social interaction time with target (one-way ANOVA: F(2,15)¼4.38, *Po0.05, n¼ 6) and (l) decreases corner zone time
(F(2,15)¼4.47, *Po0.05, n¼ 6) compared with mPFC projecting VTA neurons or HSV-LS1L-eYFP control virus. (m) There is no effect on locomotor activity
(F(2,15)¼ 3.31, *P¼0.06, n¼ 6). (n) Sucrose preference 12 h following social interaction (F(2,15)¼4.47, *Po0.05, n¼ 6). Mean±s.e.m.
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Systemic administration of KCNQ opener retigabine. To fur-
ther investigate the therapeutic potential of KCNQ channels, we
systemically administered the KCNQ opener retigabine in sus-
ceptible mice. Among the available KCNQ pharmacological
openers, retigabine (ezogabine), which stabilizes the open state of
the channel24,25, is an FDA-approved agent. Its primary
indication is as an anticonvulsant, marketed under the name
Potiga. Given its current availability and efﬁcacy as a KCNQ
channel opener in models of epilepsy, chronic pain and
mania26,27, we systemically administered retigabine to socially
defeated susceptible mice and performed behavioural testing
(Fig. 3a,b). Following eight repeated but not single
(Supplementary Fig. 4) intraperitoneal injection (i.p.) of
retigabine, susceptible mice spent more time interacting with
the social target in the interaction zone (Fig. 3c,d) and less time in
the corner zone (Fig. 3e), without adverse effects on locomotor
activity (Fig. 3f). Chronic systemic administration of retigabine
increased sucrose preference and decreased immobility time
during the FST in susceptible mice when compared with vehicle
treatment, further indicating the antidepressant effects of
retigabine (Fig. 3g,h). In contrast, repeated i.p. injections of
retigabine in stress-naive mice had no adverse behavioural effects
(Supplementary Fig. 5). Following behavioural testing of
susceptible mice, in vitro VTA slice recordings were performed
to determine if the cellular functions were regulated as a result of
retigabine administration. VTA DA neurons of susceptible mice
that received repeated systemic administration of retigabine
demonstrated a normalization of ﬁring rate as compared
with the vehicle-injected mice (Fig. 3i). These results provide a
direct systemic validation of retigabine as a potential
antidepressant that potentiates the active ion channel
mechanism of natural resilience.
Discussion
Overall, this study provides a therapeutic strategy of using active
resilient mechanisms to normalize the pathogenic hyperactivity of
VTA DA neurons. It is known that DA neurons in the brain’s
reward system have a constant baseline ﬁring to provide a
necessary level of dopamine to their target brain regions. This
baseline activity is altered differentially or even oppositely in
distinct stress models of depression such as severe social defeat
stress and mild non-social stress paradigms1,3,8,28–33, and these
opposite pathological alterations in VTA DA neurons have been
causally linked to depression-related behaviours in recent
optogenetic studies2,32. These opposing effects of different stress
models are not unexpected given the complex and diverse
aetiology of human depressive symptoms, with frequent
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Figure 2 | Microinfusion of KCNQ openers ﬂupirtine, retigabine and BMS-204352 into the VTA of susceptible mice consistently normalizes
depression-like behaviours. (a) Experimental timeline and (b) experimental design of VTA bilateral microinfusion into the VTA of susceptible mice.
(c) Social interaction behaviour is increased signiﬁcantly in susceptible mice 10min following acute infusion to the VTA with ﬂupirtine (0.3mg), retigabine
(0.1mg) or BMS-204352 (0.1mg), compared with vehicle, indicating an antidepressant-like response (ﬂupirtine: t21¼4.47, ***Po0.001; retigabine:
t20¼4.71, **Po0.01; BMS-204352: t20¼ 5.52, ***Po0.001; n¼ 10–12). (d) Corner zone time during social interaction test is signiﬁcantly reduced
compared with vehicle (ﬂupirtine: t21¼ 3.62, **Po0.01; retigabine: t20¼ 3.27, **Po0.01; BMS-204352: t20¼ 5.26, **Po0.01; n¼9–10). (e) Distance
travelled during 2.5min social interaction test (ﬂupirtine: t21¼ 2.07, P¼0.11; retigabine: t20¼ 1.38, P¼0.18; BMS-204352: t20¼ 1.28, P¼0.22; n¼9–10).
(f) Sucrose preference measured over a 12-h period after social interaction test (ﬂupirtine: t26¼ 2.07; retigabine: t26¼ 2.13; BMS-204352: t26¼ 2.14;
*Po0.05, n¼ 14). (g) Immobility time is decreased in the forced swim test following infusion to the VTA in susceptible mice indicating an antidepressant-
like response following 10min infusion (ﬂupirtine: t21¼4.15, **Po0.01; retigabine: t21¼ 3.36, **Po0.01; BMS-204352: t21¼ 3.61, *Po0.05; n¼ 10–13).
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extremes in symptomology being expressed. These extremes are
highlighted in human depression studies in which, insomnia/
hypersomnia, anorexia/overeating are among the conﬂicting
symptomology34. In the well-established chronic social defeat
model, the pathogenic hyperactivity of VTA DA neurons is, in
part, driven by intrinsic changes in channel function. These
changes maybe unique to aetiology of symptoms expressed.
Speciﬁcally, an increased Ih current (hyperpolarization-activated
cation channel-mediated current) is seen in susceptible mice3,8,
whereas the stable ﬁring found in the resilient group is
homeostatically maintained by counteracting this pathogenic
Ih current with Kþ channels3. Our current data support the
KCNQ contribution to these active Kþ channels in resilience.
Importantly, directly potentiating KCNQ channels in susceptible
mice normalizes the pathogenic hyperactivity of VTA DA
neurons, and has signiﬁcant antidepressant effects as assessed at
the behavioural level. Our study identiﬁes KCNQ channels as a
novel target to stabilize VTA DA neurons and achieve treatment
efﬁcacy following severe conditions of social stress. It is intriguing
for the future work to explore whether enhancing active resilience
mechanisms such as retigabine has a protective effect before the
onset of depression or during the induction of depression.
From a clinical-translational perspective, retigabine is currently
FDA approved for use as anticonvulsant for partial epilepsies,
indicating that it may exert its treatment effects by targeting
pathological regions of hyperactivity in the brain. Retigabine’s
powerful normalization of the pathogenic hyperactivity of VTA
DA neuron activity is a locus for an anti-depressive therapeutic
effect, although it may not be the only site of efﬁcacy. In addition
to retigabine’s use for treatment of partial-onset seizures, recent
research has indicated it has a wide array of potential uses ranging
from treating amyotrophic lateral sclerosis, chronic pain to
alcohol addiction35–38. Although potential negative effects of
systemic KCNQ potentiation in patients have to be considered,
our studies identify KCNQ channels as a promising previously
uncharacterized target in treatment of major depressive disorder.
Overall, our data support the concept of an ‘active’ antidepressant
that utilizes active ionic resilience mechanisms and thereby pave
the way for a novel, urgently needed treatment strategy for
patients with depression.
Methods
Mice. This study used TH-BAC-Cre39, and GAD2-IRES-Cre40 mice with
C57BL/6J gene background that were bred at Icahn School of Medicine at Mount
Sinai and used at 8 weeks, the age at start of experimental manipulations.
Wild-type 7-week-old male C57BL/6J mice were ordered from Jackson Laboratory
for some studies. These mice were acclimated to the housing facility for 1 week
prior to experiments. As in our previous studies1–3, all mice were group housed
and maintained on a 12-h light, 12-h dark cycle with ad libitum access to food and
water until start of experiments. Following chronic social defeat stress, mice were
then singly housed and maintained on a 12-h light, 12-h dark cycle with ad libitum
access to food and water. All experiments performed are approved by the
Institutional Animal Care and Use Committee and comply with institutional
guidelines for Animal Care and Use Committee set forth by Icahn School of
Medicine at Mount Sinai.
Chronic social defeat stress paradigm. Chronic social defeat stress was
performed according to published protocols1–3,41. Brieﬂy, CD1 aggressive mice
were housed in social defeat cages (26.7 cm width 48.3 cm depth 15.2 cm
height; Allentown Inc.) 24 h before the start of defeats on one side of a clear
perforated Plexiglass divider. During each defeat episode, C57BL/6J or TH-BAC-
Cre mice were allowed to interact for 10min with an aggressive CD1 mouse, during
which these mice undergo a physical bout of interaction. For the remainder of the
day, the C57BL/6J or TH-BAC-Cre mouse is then housed across a clear plexiglass
divider providing further sensory cues. After 10 bouts of defeat occurring, over 10
consecutive days the C57BL/6J or TH-BAC-Cre mice were singly housed. Mice
underwent the social interaction test 24 h after the ﬁnal defeat episode. Control
mice were housed two mice per cage divided by a perforated plexiglass divider and
rotated similar to the defeat mice.
Social interaction test. Social interaction testing was performed as previously
described1–4,41. The social interaction test, measured the time spent in the
interaction zone, corner zones and locomotor activity during the ﬁrst (CD1 target
absent in interaction zone) and second (CD1 target present in interaction zone)
trials in an open-ﬁeld arena. Their movements were automatically monitored and
recorded (Ethovision 10.0, Noldus Information Technology) for 2.5min each test
session. Behavioural phenotyping was performed on day 11. The segregation of
susceptible and resilient mice was based on the social interaction ratio, which was
calculated as (100 (interaction time, target present)/(interaction time, target
absent)) as described previously1–3,41. Social interaction behaviour was then
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timeline and (b) experimental design of repeated intraperitoneal (i.p.) injections of retigabine in susceptible mice. (c,d) Social interaction behaviour post
repeated i.p. injections of retigabine in susceptible mice shows an increase in the time spent in the interaction zone (t16¼4.02, **Po0.01, n¼ 9) and
(e) a decrease in time spent in the corner zone (t16¼ 2.65, *Po0.05, n¼ 9) compared with vehicle. (f) No adverse effects on locomotor activity (t16¼ 1.23,
P¼0.24, n¼9). (g) Sucrose preference increased following repeated i.p. retigabine when compared with vehicle injections (t10¼ 2.79, *Po0.05, n¼6).
(h) Following repeated i.p. injections of retigabine there is a signiﬁcant reduction of immobility time during the forced swim test in susceptible mice
(t10¼ 2.48, *Po0.05, n¼6). (i) The hyperactivity of VTA neurons is normalized in susceptible mice (t66¼ 3.64, ***Po0.001, n¼ 34 cells, 7 mice per
group). Means±s.e.m.
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calculated as total time spent in each zone or as a ratio of the time spent in the
interaction with target present divided by the time spent in the interaction zone
with the target absent. All mice with a ratio above 100 were classiﬁed as resilient,
and all mice below 100 were classiﬁed as susceptible.
Sucrose preference. To determine if mice developed anhedonic responses to the
experimental manipulations, a sucrose preference test was performed1–3. For
sucrose-preference testing, a solution of 1% sucrose or drinking water was ﬁlled in
50ml tubes with stoppers ﬁtted with ball-point sipper tubes (Ancare). All animals
were singly housed and acclimatized to two-bottle choice conditions prior to
testing conditions. Twelve hours post social interaction, ﬂuid was weighed, and the
positions of the tubes were interchanged. Sucrose preference was calculated as a
percentage (100 volume of sucrose consumed (in bottle A)/total volume
consumed (bottles A and B)). The preference for sucrose over water is a measure of
anhedonic reward sensitivity.
Forced swim test. The FST was performed as previously described3. Ten minutes
following infusion mice were placed for 6min in a 4-l Pyrex glass beaker containing
3 l of water at 24±1 C. The water was changed between test subjects. All test
sessions were recorded by a digitally tracking Ethovision program, positioned on
the side of the beaker to record mouse movements. Time spent immobile was
independently analysed by Ethovision 10.0 software. Increased immobility time
and decreased latency to immobility is a measure of behavioural despair. Sample
heatmap of activity was automatically generated in Ethovision 10.0 (Noldus
Information Technology).
Electrophysiology. Acute coronal brain slices of VTA were prepared according to
previously published protocols2,3. All recordings were carried out blind to drug
treatment. Male 8–12-week-old mice were perfused with cold artiﬁcial
cerebrospinal ﬂuid (aCSF) containing (in mM): 128 NaCl, 3 KCl, 1.25 NaH2PO4,
10 D-glucose, 24 NaHCO3, 2 CaCl2 and 2 MgCl2 (oxygenated with 95% O2 and 5%
CO2, pH 7.35, 295–305mOsm). Acute brain slices containing the VTA were cut
using a microslicer (DTK-1000, Ted Pella) in sucrose-ACSF, which was derived by
fully replacing NaCl with 254mM sucrose, and saturated by 95% O2 and 5% CO2.
Slices were maintained in the holding chamber for 1 h at 37 C. Slices were
transferred into a recording chamber ﬁtted with a constant ﬂow rate of aCSF
equilibrated with 95% O2 and 5% CO2 (2.5mlmin 1) and at 35 C. Glass
recording pipettes (2–4MO) were ﬁlled with an internal solution containing (mM):
115 potassium gluconate, 20 KCl, 1.5 MgCl2, 10 phosphocreatine, 10 HEPES, 2
magnesium ATP and 0.5 GTP (pH 7.2, 285mOsm). VTA DA neurons were
identiﬁed by their location and infrared differential interference contrast
microscopy and recordings were made from TH positive neurons in eYFP virally
tagged neurons. Firing rate was recorded in the cell-attach mode, and data
acquisition and on-line analysis of ﬁring rate were collected using a Digidata 1440A
digitizer and pClamp 10.2 (Axon Instruments). The sequence and timing of
recordings is consistent throughout treatment groups.
Immunohistochemistry. Mice were perfused with 30ml cold PBS and 30ml 4%
paraformaldehyde (PFA). The brain were taken out and post-ﬁxed with same
ﬁxative overnight, then treated with 30% sucrose at 4 C for 2 days. Brain tissue was
sectioned with thickness of 30 mm and stored in at 4 C till use. Brain sections were
rinsed with PBS and blocked with blocking buffer (BSA, PBS with 0.2% Triton
X-100) for 1 h. Sections were incubated with primary Anti-TH monoclonal
antibody (Sigma 1:10,000) and anti-GFP (Invitrogen 1:1,000) at 4 C. Next day,
sections were incubated with secondary (Alexa Fluor 488 and Cy5) for 1 h. Then
rinse with PBS three times before mounting. Z-stack, tile scans and single images
were acquired using Zeiss 880 laser scanning confocal microscope equipped with a
32-spectral array GaAsp detector (Carl Zeiss, Jena, Germany) using  20
Plan-Apochromat objective. eYFP labelled with Alexa 488 antibody was excited
using 488 nm argon ion laser line and the ﬂuorescence emission was collected from
491 to 600 nm. Alexa 647 was excited using a 633-nm HeNe laser line and the
ﬂuorescence emission was collected from 638 to 759 nm. Images presented are
maximum projection intensity images from 20 z-slices with a thickness 1.0 mm per
slice. Images were analysed using the ZEN 2014 software.
Cannula implantation. Cannula implantation surgeries were performed as
described in our previous work3,6. Mice were anaesthetized by the intraperitoneal
injection of a mixture ketamine (100mg kg 1) and xylazine (10mg kg 1)
anaesthesia and placed into a stereotaxic apparatus (David Kopf Instruments,
Tujunga, California). Mice were bilaterally implanted with a stainless 26 gauge
cannulae ﬁtted with obturators (Plastics One) targeting directly above the VTA
with the following coordinates: anteroposterior  3.3mm; lateral 0.5mm;
dorsoventral  3.7mm. The cannulae were secured with dental cement (Dentsply);
the mice were then singly housed and allowed to recover for 5 days.
VTA microinfusion. Following cannuale surgery and recovery mice received an
acute intra-VTA infusion of XE-991, ﬂupirtine, retigabine, BMS-204352 or ﬁltered
1 PBS as vehicle control. All drugs were prepared daily and are available for
commercial purchase (Tocris, Alomone, Sigma). Simultaneous bilateral
microinjections were delivered through an injector cannula in a total volume of
0.4 ml per side at a continuous rate of 0.1 ml min 1 under the control of a
microinfusion pump (Harvard Apparatus). Concentrations were selected based on
earlier in vivo studies21,26. Injectors were removed 5min after the stopping of each
infusion, and mice remained undisturbed in their home cages prior to social
interaction behaviour. All cannulae placements were conﬁrmed post mortem.
Stereotaxic surgery and viral gene transfer. We performed all surgeries under
aseptic conditions using anaesthetic as described previously2,3,6. TH-Cre mice were
anaesthetized with a mixture of ketamine (100mg kg 1) and xylazine
(10mg kg 1), positioned in a small-animal stereotaxic instrument (David Kopf
Instruments), and the skull surface was exposed. To selectively target DA neurons
in the VTA, we utilized a combination of TH-Cre mice and a Cre inducible
HSV-LSIL-KCNQ3-eYFP virus to overexpress the KCNQ3 channels, similar to our
previous studies. To selectively target neurons in the VTA that project to the
Nucleus accumbens or medial prefrontal cortex, we utilized a duel virus approach
in C57BL/6J mice. A combination of a retrograding AAV2/5-Cre virus injected
into the NAc (bregma coordinates: AP, þ 1.5; LM, þ 1.6; DV, –4.4; 10 angle) or
mPFC (bregma coordinates: AP, þ 1.7; LM, þ 1.6; DV, –2.5; 15 angle) and a Cre
inducible HSV-LSIL-KCNQ3-eYFP virus to overexpress the KCNQ3 channels in
the VTA. Therefore, KCNQ3 was expressed selectively in NAc or mPFC projecting
neurons in the VTA. These viruses were provided by Rachael Neve’s laboratory in
Massachusetts Institute of Technology (MIT) and the University of Pennsylvania
vector core. Thirty-three-gauge syringe needles (Hamilton Co.) were used to
bilaterally infuse 0.5 ml of virus HSV-LS1L-KCNQ3-eYFP or HSV-LS1L-eYFP into
the VTA at a 7 angle (bregma coordinates: AP, þ 3.3mm; LM, þ 1.0mm; DV,
 4.6mm) at a rate of 0.1 ml min 1. All behavioural analyses were conducted days
3–4 after infusion during maximal HSV expression.
Retigabine treatment. After social interaction testing, mice were sorted into
either susceptible or resilient phenotypes on the basis of their social interaction
ratio as described above. Control mice were housed identically to defeated mice for
the duration of the experiment but were never exposed to social defeat sessions.
Susceptible and control subgroup mice were used and randomly divided into
treatment groups. For each group (control or susceptible), mice received
either daily i.p. injections of retigabine (1mg kg 1 body weight) for 8 days or
vehicle i.p. injections. All mice then underwent a social interaction test 24 h post
ﬁnal injection. Immediately following the social interaction test, one subset of mice
underwent sucrose preference, one subset underwent FST and a third group
underwent VTA slice recordings with measurements of ﬁring rate.
Statistics. All analyses were performed with Prism software. Comparisons were
achieved by means of analyses of variance with/without repeated factors (ANOVA;
multiple-groups comparisons). In the latter case, post hoc comparisons (Tukey)
were performed when appropriate. When appropriate, a two-way Student’s t-tests
were used to determine statistical signiﬁcance of planned comparisons. Data are
expressed as the mean±s.e.m. Statistical signiﬁcance was set at Po0.05.
Data availability. All relevant data are included within the manuscript’s ﬁgures or
in supplementary ﬁles. Any additional data is available upon request from the
corresponding author.
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